Fig. 4: Clinical benefit in relation to vaccine-induced immunity.

a Swimmer plot of the 26 patients indicating the progression free survival and overall survival. Data is given per cohort (20 µg (orange), 40 µg (green), 100 µg (blue) peptide and 100 µg peptide + pembrolizumab (purple)). The patients with PR and MR are indicated. The duration of SD reaches from the assessment at week 9 until the symbol indicating PD. The SD of patients #6, 16, 23, and 24 were confirmed. Symbols indicate: plus sign: deceased, asterisk: new treatment started, red triangle: progression of disease, black square: pembrolizumab continued. c, d Kaplan-Meier curves showing (b) the overall survival of 26 patients with (orange; median 12.69 (CI = 9.21-undefined) months) and without (light blue; median 8.6 (CI = 3.57-undefined) months) clinical benefit after vaccination, and (c) progression free (median 2.08, CI = 2.07-4.20 months) and (d) overall survival (median 9.37 (CI = 6.13-16.89) months) of the entire patient cohort. e Percentage of vaccine-induced LRPAP1_{21-30S_V}-specific CD8⁺ T cells in patients with (yes; orange) or without (no; light blue) a PR, SD or MR after vaccination. Data is represented as scatter plot with bars indicating mean and dots representing individual data points. Statistical analysis (b, c, d) by non-parametric log rank tests and (e) two-tailed, unpaired non-parametric Mann-Whitney U test. Source data are provided as a Source Data file.